A JAK inhibitor for treatment of rheumatoid arthritis: the baricitinib experience
Baricitinib, an oral selective Janus kinase (JAK)1/JAK2 inhibitor, is approved as monotherapy or in combination with methotrexate for treating adults with moderate-to-severe active rheuma-toid arthritis (RA) and provides improvements in clinical signs, symptoms and patient-reported outcomes. Current...
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Sprache: | English |
| Veröffentlicht: |
MDPI
2023
|